🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

Carl Zeiss Meditec's share price target cut by JPMorgan after EBIT forecast slash

EditorEmilio Ghigini
Published 2024/06/18, 10:02
AFXG
-

On Tuesday, JPMorgan made adjustments to its expectations for Carl Zeiss Meditec AG (AFX:GR) (OTC: CZMWY), reducing the share price target to EUR56.00 from EUR68.00 while keeping an Underweight rating on the stock.

This revision came after the company issued a profit warning that preceded its third-quarter results, indicating a significant reduction in its forecast for the second half of the fiscal year 2024 earnings before interest and taxes (EBIT).

The company's shares experienced a sharp decline, closing down 20% on Monday. The reduction in the financial outlook was more substantial than market expectations, with a cut greater than 40% to the H2 EBIT projections. This move aligns with the previously signaled concerns from JPMorgan, which had anticipated a downward adjustment in the company's financial performance.

Despite the adjustment to the company's forecasts, JPMorgan has chosen to maintain its Underweight rating. The firm sees persistent risks and anticipates further downward revisions to the fiscal year 2025 and mid-term expectations.

In response to these developments, JPMorgan has decreased its earnings per share (EPS) estimates for Carl Zeiss Meditec by 22% for fiscal year 2024 and by 19% for fiscal year 2025.

With these revised estimates, Carl Zeiss Meditec's shares are now valued at 35 times and 27 times the expected earnings for fiscal years 2024 and 2025, respectively. JPMorgan continues to view the valuation as challenging, suggesting a cautious outlook on the company's future financial performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.